Aardvark Therapeutics, Inc Common Stock

Yahoo Finance • 4 days ago

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy fr... Full story

Yahoo Finance • 20 days ago

Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Carvana What happened? On Mond... Full story

Yahoo Finance • last month

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) N... Full story

Yahoo Finance • 2 months ago

Datadog, Trade Desk upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: KeyBanc upgraded Datadog (DDOG) to Overw... Full story

Yahoo Finance • 3 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathw... Full story

Yahoo Finance • 4 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 4 months ago

Aardvark Therapeutics GAAP EPS of -$0.66

* Aardvark Therapeutics press release [https://seekingalpha.com/pr/20200202-aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and] (NASDAQ:AARD [https://seekingalpha.com/symbol/AARD]): Q2 GAAP EPS... Full story

Yahoo Finance • 4 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 ST... Full story

Yahoo Finance • 5 months ago

Aardvark reports weight loss benefits of ARD-201 in preclinical study

SAN DIEGO - Aardvark Therapeutics, Inc. (NASDAQ:AARD), a $242 million market cap biotech company with a strong financial health score according to InvestingPro, announced Tuesday that its investigational drug ARD-201 demonstrated approxima... Full story

Yahoo Finance • 5 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseas... Full story

Yahoo Finance • 6 months ago

H.C. Wainwright initiates coverage on Aardvark Therapeutics stock with Buy rating

Investing.com - H.C. Wainwright initiated coverage on Aardvark Therapeutics Inc (NASDAQ:AARD) Monday with a Buy rating and a $40.00 price target. According to InvestingPro data, analyst targets for AARD range from $20 to $50, with the st... Full story

Yahoo Finance • 6 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathwa... Full story

Yahoo Finance • 7 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SA... Full story

Yahoo Finance • 9 months ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average... Full story